Assessment of the vascularization of neuroendocrine tumors by stimulated acoustic emission of SH U 508A ultrasound contrast agent and color or power Doppler sonography

Investigative Radiology

Volumn 35, Issue 4, 2000, Pages 253-259

  Ricke, Jens ^a   Hänninen, Enrique Lopez ^a   Amthauer, Holger ^a   Lemke, Arne ^a   Felix, Roland ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Doppler sonography; Neuroendocrine tumor; Stimulated acoustic emission; Ultrasound contrast agent

Indexed keywords

SHU 508;

ARTICLE; COLOR ULTRASOUND FLOWMETRY; CONTRAST ENHANCEMENT; DIGITAL SUBTRACTION ANGIOGRAPHY; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR BLOOD FLOW; TUMOR SCINTISCANNING; TUMOR VASCULARIZATION;

EID: 0034044056     PISSN: 00209996     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004424-200004000-00006     Document Type: Article

References (29)

1. Forsberg F, Merton DA, Liu JB, Needleman L, Goldberg BB. Clinical applications of ultrasound contrast agents. Ultrasonics 1998;36: 695-701.
2. Calliada F, Campani R, Bottinelli O, Bozzini A, Sommaruga MG. Ultrasound contrast agents: Basic principles. Eur J Radiol 1998; 27(suppl 2):S157-S160.
3. Nanda N, Carstensen EL. Echo-enhancing agents: safety. In: Nanda N, Schlief R, Goldberg BB, eds. Advances in echo imaging using contrast enhancement. 2nd ed. Lancaster, England: Kluwer Academic; 1997:115-131.
4. Schlief R. Developments in echo-enhancing agents. Clin Radiol 1996; 51(suppl 1):5-7.
5. Albrecht T, Blomley MJ, Cosgrove DO, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:1579-1583.
6. Willam C, Maurer J, Schroeder R, et al. Assessment of vascularity in reactive lymph nodes by means of D-galactose contrast enhanced Doppler sonography. Invest Radiol 1998;33:146-152.
7. Schroeder RJ, Maeurer J, Vogl TJ, et al. D-Galactose-based signal-enhanced color Doppler sonography of breast tumors and tumorlike lesions. Invest Radiol 1999;34:109-115.
8. Blomley MJ, Albrecht T, Cosgrove DO, et al. Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: Early experience. Radiology 1999;210:409-416.
9. Hauff P, Fritzsch T, Reinhardt M, et al. Delineation of experimental liver tumors in rabbits by a new ultrasound contrast agent and stimulated acoustic emission. Invest Radiol 1997;32:94-99.
10. Andersson T, Erikkson B, Hemmingson A, Lindgren PG, Öberg K. Angiography, CT, MRI and ultrasonography in the detection of liver metastases from endocrine gastrointestinal tumors. Acta Radiol 1987;28:535-539.
11. Wallace S, Ajani JA, Charnsangavej C, et al. Carcinoid tumors: Imaging procedures and interventional radiology. World J Surg 1996;20:147-156.
12. Ruszniewski P, Rougier P, Roche A, et al. Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors: A prospective phase II study in 24 patients. Cancer 1993;71:2624-2630.
13. Therasse E, Breittmayer F, Roche A, et al. Transcatheter chemoembolization of progressive carcinoid liver metastases. Radiology 1993;189:541-547.
14. Rubin JM, Bude RO, Carson PL, Bree RL, Adler RS. Power Doppler US: A potentially useful alternative to mean frequency-based color Doppler US. Radiology 1994;190:853-856.
15. Geigy scientific tables. 8th ed. Basle, Switzerland: Geigy; 1980:89-102.
16. Wilander E, Lundquist M, Öberg K. Gastrointestinal carcinoid tumors: Histogenetic, histochemical, immunohistochemical, clinical and therapeutic aspects. Prog Histochem Cytochem 1989;19:1-87.
17. Capella C, Heitz PU, Höfler H, Solcia E, Kloppel G. Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 1995;425:547-560.
18. Öberg K. Neuroendocrine gastrointestinal tumors. Ann Oncol 1996;7: 453-463.
19. Caplin ME, Buscombe JR, Hilson AJ, Jones AL, Watkinson AF, Burroughs AK. Carcinoid tumor. Lancet 1998;352:799-805.
20. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813-829.
21. Godwin JD II. Carcinoid tumors: An analysis of 2837 cases. Cancer 1975;36:560-569.
22. Wiedenmann B, Jensen RT, Mignon M, et al. Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: General recommendations by a consensus workshop. World J Surg 1998;22:309-318.
23. Brown KT, Koh BY, Brody LA, et al. Particle embolization of hepatic neuroendocrine metastases for control of pain and hormonal symptoms. J Vasc Intervent Radiol 1999;10:397-403.
24. Steger W, Vogl TJ, Hosten N, Steger S, Hidajat N, Felix R. Doppler sonographic monitoring control of perfusion of hepatocellular carcinoma after arterial chemoembolization. Fortschr Rontgenstr 1998;168:49-56.
25. Terris B, Scoazec JY, Rubbia L, et al. Expression of vascular endothelial growth factor in digestive neuroendocrine tumors. Histopathology 1998;32:133-138.
26. Konno H, Arai T, Tanaka T, et al. Antitumor effect of a neutralizing antibody to vascular endothelial growth factor on liver metastasis of endocrine neoplasm. Jpn J Cancer Res 1998;89:933-939.
27. Lopez Hanninen E, Vogl TJ, Bechstein WO, et al. Biphasic spiral computed tomography for detection of hepatocellular carcinoma before resection or orthotopic liver transplantation. Invest Radiol 1998;33:216-221.
28. Hanafusa K, Ohashi I, Himeno Y, Suzuki S, Shibuya H. Hepatic hemangioma: Findings with two-phase CT. Radiology 1995;196: 465-469.
29. Choi BI, Kim TK, Han JK, Chung JW, Park JH, Han MC. Power versus conventional color Doppler sonography: Comparison in the depiction of vasculature in liver tumors. Radiology 1996;200:55-58.